ArticleKidney3602026
Impact of Apolipoprotein L1-Associated Pregnancy Complications on Kidney Disease Phenotypes in a HIV-Associated Nephropathy Mouse Model.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
key pointsG0 coexpression did not improve CKD outcomes in a mouse model of HIV-associated nephropathy. Apolipoprotein L1 is expressed in the placenta, and risk variants are associated with preeclampsia, low birth weight, and reduced podocyte and glomerular density. Apolipoprotein L1 kidney disease risk may be mediated by apolipoprotein L1-associated birth complications negatively affecting kidney development.
backgroundApolipoprotein L1 (APOL1) polymorphisms are a significant risk factor of kidney disease including HIV-associated nephropathy (HIVAN), but a comprehensive understanding of the pathogenic mechanism remains unclear.
methodsAPOL1 transgenic models expressing APOL1 -G0 and the kidney disease risk-associated APOL1 -G1 variant were intercrossed with the Tg26 mouse model of HIVAN. Because all these transgenic models are hemizygous, crosses produced offspring of four genotypes: wild-type (WT) mice, APOL1 , Tg26, and dual transgenic mice expressing both APOL1 and Tg26 transgenes. Kidney function, pathology, and transgene expression patterns were examined in addition to podocyte and glomerular densities.
resultsThe WT and APOL1 G0 or G1 mice did not develop kidney disease, whereas Tg26 and dual transgenic mice developed severe kidney disease consistent with the Tg26 HIVAN phenotype. The outcome of the G1/Tg26 intercross was expressed during pregnancy with neonatal complications that included a preeclampsia-like phenotype, low fetal/placental weight ratios, low birth weights, and fewer dual transgenic offspring that survived to adulthood. Some adult offspring from the G1/Tg26 intercross also had reduced podocyte densities and fewer glomeruli. This included the WT and APOL1 -G1 mice, suggesting a systemic effect of the preeclampsia phenotype on the entire litter. The G0/Tg26 intercross also demonstrated kidney pathology and albuminuria similar to the G1/Tg26 intercross.
conclusionsCoexpression of G0 in the Tg26 mouse model was not protective against kidney disease. In addition, the G1-associated pregnancy complications, reduced podocyte and glomerular densities, suggest a second mechanism by which APOL1 risk variant expression may affect long-term kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.